Pharmaceutical composition for preventing and treating periodontal diseases comprising alnus plant extract as active ingredient, food composition for improving periodontal diseases comprising same, toothpaste or mouthwash composition and feed comprising same

Abstract

The problem to be solved by the present invention is to provide a substance for preventing, treating or improving periodontal diseases.SOLUTION: Provided are a pharmaceutical composition for preventing and treating periodontal diseases comprising a Alnus plant extract as an active ingredient, a food composition for improving periodontal diseases comprising the same, and a toothpaste or mouthwash composition and a feed comprising the same, wherein the Alnus plant extract according to the present invention comprises oregonin or aglycoform thereof and has excellent effects of improving, preventing and treating periodontal diseases.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] The present invention relates to a pharmaceutical composition for preventing and treating periodontal disease, which contains an extract from a plant of the genus Alder as an active ingredient, a food composition for improving periodontal disease, and a toothpaste or mouthwash composition and feed containing the same. [Background technology]

[0002] Periodontal disease refers to a group of diseases that occur in periodontal tissues and is divided into gingivitis and periodontitis depending on the severity of the disease. Gingivitis is a relatively mild and rapidly reversible form of periodontal disease in which inflammation is limited to the gums, i.e., soft tissue, while periodontitis refers to a condition in which inflammation has progressed to the gums and surrounding alveolar bone. Periodontal disease is not only a major cause of tooth loss over time, but has also been reported to be highly associated with systemic diseases such as dementia, arteriosclerosis, myocardial infarction, and stroke. As modern society enters an aging phase, there is growing interest in the prevention and treatment of periodontal disease.

[0003] Alnus spp., a member of the Betulaceae family, is distributed throughout the Northern Hemisphere, including Korea, the United States, Japan, and China, with 17 species known to grow wild in Japan, including Alnus japonica Steudel. (1, 2) The most distinctive compounds found in Alnus spp. are diarylheptanoid compounds, and many researchers have discovered that these compounds are present in Alnus spp. Numerous reports have been published on oregonin, a diarylheptanoid glycoside, which was isolated and structurally determined by tracing the reddish-brown discoloration that occurs when alder trees (A. rubura, A. hirsuta, A. japonica) are cut. Many researchers around the world have also reported numerous studies using oregonin as an indicator substance (see Patent Document 0001: Korean Patent Publication No. 10-2009-0061128, (Patent Document 0002): Korean Registered Patent No. 10-1756020, (Patent Document 0003): Korean Patent Publication No. 10-2018-0085636, (Patent Document 0004): Korean Registered Patent No. 10-2217551).

[0004] However, there has been no specific report on the preventive and therapeutic properties of alder extracts and their active ingredients for periodontal diseases such as gingival inflammation. Summary of the Invention [Problem to be solved by the invention]

[0005] Therefore, the problem to be solved by the present invention is to provide a substance that prevents, treats or improves periodontal disease. [Means for solving the problem]

[0006] To achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating periodontal disease, which comprises an extract of an Alnus plant as an active ingredient.

[0007] In one embodiment of the present invention, the alder extract contains any one of the following compounds:

[0008] [C1] [ka]

[0009] [C2] [ka]

[0010] [C3] [ka]

[0011] In one embodiment of the present invention, the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

[0012] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

[0013] The present invention provides a food composition for preventing and improving periodontal disease, which comprises an extract of an Ulmus plant as an active ingredient.

[0014] In one embodiment of the present invention, the alder extract contains any one of the following compounds:

[0015] [C1] [ka]

[0016] [C2] [ka]

[0017] [C3] [ka]

[0018] In one embodiment of the present invention, the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

[0019] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

[0020] The present invention also provides a toothpaste or mouthwash composition comprising an extract of an Ulmus plant as an active ingredient.

[0021] In one embodiment of the present invention, the alder extract contains any one of the following compounds:

[0022] [C1] [ka]

[0023] [C2] [ka]

[0024] [C3] [ka]

[0025] In one embodiment of the present invention, the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

[0026] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract.

[0027] The present invention also provides a feed containing an extract of an Ulmus plant as an active ingredient.

[0028] In one embodiment of the present invention, the alder extract contains any one of the following compounds:

[0029] [C1] [ka]

[0030] [C2] [ka]

[0031] [C3] [ka]

[0032] In one embodiment of the present invention, the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

[0033] In one embodiment of the present invention, the pharmaceutical composition for preventing and treating periodontal disease further comprises an elm extract. [Effects of the Invention]

[0034] The pharmaceutical or food composition for preventing and treating periodontal disease, which contains the extract of an Alder plant according to the present invention as an active ingredient, contains oregonin or its non-glycosylated form and has excellent effects in improving, preventing and treating periodontal disease. [Brief explanation of the drawings]

[0035] [Figure 1] 1 is a diagram showing the steps of an extraction method for obtaining an alder extract according to one embodiment of the present invention. [Figure 2] 1 is a diagram showing the steps of an extraction method for obtaining an alder extract according to one embodiment of the present invention. [Figure 3] 1 is a diagram showing the steps of an extraction method for obtaining an alder extract according to one embodiment of the present invention. [Figure 4] FIG. 1 is a step diagram of a method for obtaining a peach and elm wood composite extract according to one embodiment of the present invention. [Figure 5] The results of TLC analysis of the obtained extract are shown below. [Figure 6] This is the result of TLC monitoring to understand the changes in components during enzymatic decomposition. [Figure 7] 1 shows the calibration curve results for oregonin. [Figure 8] 1 shows the results of HPLC analysis of oregonin components in extract AJ60E. [Figure 9] 1 shows the results of HPLC analysis of oregonin components in extract AJRF1. [Figure 10] 1 shows the results of HPLC analysis of oregonin components in extract AJRF2. [Figure 11] 1 shows the results of HPLC analysis of hirsutanonol and hirsutenonone components in extract AJ60E. [Figure 12] 1 shows the results of HPLC analysis of hirsutanonol and hirsutenonone components in extract AJRF1. [Figure 13] 1 shows the results of HPLC analysis of hirsutanonol and hirsutenonone components in extract AJRF2. [Figure 14] This shows the results of analyzing the amount of TNFα expression when treated with each extract. [Figure 15] This shows the results of analyzing the amount of IL-6 expression when treated with each extract. [Figure 16] This shows the results of analyzing the amount of IL-1β expression when treated with each extract. DETAILED DESCRIPTION OF THE INVENTION

[0036] Hereinafter, specific embodiments of the present invention will be described with reference to the drawings, but these are merely examples and the present invention is not limited thereto.

[0037] In describing the present invention, if it is determined that a detailed description of known art related to the present invention may unnecessarily obscure the gist of the present invention, the detailed description will be omitted. Furthermore, the terms used below are defined in consideration of the functions of the present invention, and may vary depending on the intentions or practices of users or operators. Therefore, the definitions should be based on the overall content of this specification.

[0038] The technical concept of the present invention is determined by the claims, and the following examples are merely a means for efficiently explaining the technical concept of the present invention to those skilled in the art to which the present invention pertains.

[0039] In the present invention, the solvent extraction process can be carried out by filtering the extract after preparation, or by concentrating or drying the extract to partially or completely remove the extraction solvent. Partial removal refers to concentrating until an aqueous concentrate free of a significant amount of organic solvent is obtained, while complete removal can result in a dry residue. For example, filtration can be carried out using filter paper or a vacuum filter, concentration can be carried out using a vacuum concentrator, and drying can be carried out using a freeze-drying method, but is not limited to these.

[0040] In the present invention, the term "extract" has the meaning commonly used in the art as a crude extract, as described above, but in a broader sense also includes fractions obtained by further fractionating the crude extract. The fractionation with a solvent may be carried out through an additional extraction step using the solvent.

[0041] As used herein, the term "containing as an active ingredient" means that the extract of the present invention contains an amount sufficient to achieve the efficacy of preventing and treating muscle loss.

[0042] As used herein, the term "periodontal disease" refers to a disease that occurs in periodontal tissues, and the term "prevention" as used in the present invention refers to any action that inhibits or delays the onset of periodontal disease by administering the pharmaceutical composition according to the present invention. Furthermore, the term "treatment" as used in the present invention refers to any action that improves or favorably alters the symptoms of periodontal disease by administering the pharmaceutical composition according to the present invention. The term "improvement" as used in the present invention refers to any action that at least reduces the parameters associated with the condition being treated, for example, the severity of symptoms. In this regard, the functional food composition may be used simultaneously or separately with a therapeutic drug for the prevention or amelioration of periodontal disease, either before or after the onset of the disease.

[0043] The pharmaceutical composition for preventing and treating periodontal diseases of the present invention may further comprise a pharmaceutically acceptable carrier, excipient, or diluent.

[0044] In the compositions of the present invention, pharmaceutically acceptable carriers are those commonly used in pharmaceutical formulations, including, but not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oil. In addition to the above ingredients, the pharmaceutical compositions of the present invention may further contain lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).

[0045] The pharmaceutical composition of the present invention can be administered orally or parenterally. In the case of parenteral administration, it can be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, etc.

[0046] The appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as formulation method, administration method, age, weight, sex, pathological condition, diet of the patient, administration time, administration route, excretion rate and reaction sensitivity, and an ordinarily skilled physician can easily determine and prescribe an effective dosage for the desired treatment or prevention.

[0047] The pharmaceutical composition for preventing and treating periodontal disease of the present invention may contain other pharmaceutically active ingredients in addition to the extract of an alder plant as an active ingredient, or may be mixed with a pharmaceutical composition containing other active ingredients.

[0048] The food or health functional food composition of the present invention may further contain a nutritively acceptable food supplement additive. Examples of nutritively acceptable food supplement additives that can be used in the present invention include, but are not limited to, natural carbohydrates such as sugars (e.g., glucose, fructose, maltose, sucrose, dextrin, and cyclodextrin) and sugar alcohols (e.g., xylitol, sorbitol, and erythritol), natural flavors (e.g., thaumatin and stevia extract), synthetic flavors (e.g., saccharin and aspartic acid), colorants, pectinic acid or its salts, alginic acid or its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, and carbonating agents. The food composition of the present invention may be in a form selected from the group consisting of powder, granules, tablets, capsules, candy, chewing gum, jelly, and beverage. The content of the alder extract in the food composition is appropriately selected taking into account the form, flavor, and taste of the food, and may range, for example, from 0.01 to 30% by weight of the total food weight. It is obvious to those skilled in the art that the form, composition, and production method of the food composition according to the present invention can be appropriately selected from conventional techniques known in the art.

[0049] In order to solve the above-mentioned problems, the present invention provides a pharmaceutical composition for preventing and treating periodontal disease, which contains an extract of a plant of the genus Alder as an active ingredient, and a health functional food for improving periodontal disease, which contains the same. [Example]

[0050] MODE FOR CARRYING OUT THE INVENTION Example 1 1 to 3 are step diagrams of an extraction method for obtaining an alder extract according to one embodiment of the present invention.

[0051] Referring to Figure 1, 8 kg of alder bark-containing branches were extracted with 60% alcohol at room temperature for 3 to 5 days. After extraction, the extract was filtered through filter paper (HDmicro, No. 20) and concentrated under reduced pressure. After concentration was complete, the extract was freeze-dried for 3 days in a freeze dryer, and 483.31 g of the extract (AJ60E) was recovered.

[0052] Thereafter, solvent fractionation proceeds as shown in FIG.

[0053] Referring to Figure 2, 200 g of the obtained product (AJ60E) was dissolved in 1 L of distilled water per 5 g, and then filtered through filter paper. The diluted AJ60E solution and ethyl acetate were subjected to solvent fractionation at a ratio of 1:1.5. The ethyl acetate (EA) layer and aqueous layer were then collected and concentrated using a vacuum concentrator. After lyophilization, 74.39 g of the extract was recovered. This EA extract was AJRF1, a high-content extract derived from Orinum spp.

[0054] FIG. 3 differs from FIG. 2 in that it is a step diagram for enzymatically decomposing AJ60E obtained in FIG.

[0055] 3, 20 g of J60E was dissolved in 850 ml of distilled water, and 75 ml of enzymes were added. The mixture was stirred at about 55° C. for 24 hours to react. The enzymes used were Pectinex Ultra SP-L and Pectinex Ultra Pulp / Novozymes.

[0056] After 24 hours, the enzymes were inactivated by heating, and then centrifuged at 10,000 rpm for 15 minutes at 4°C. The supernatant was then collected using filter paper, and mixed with ethyl acetate in a 1:1 ratio, followed by solvent fractionation using a separatory funnel. The EA layer was then collected using filter paper, and the aqueous layer was again subjected to solvent fractionation with fresh EA, obtaining approximately 2 L of EA layer. The mixture was then concentrated under reduced pressure to obtain a total of 89 g (AJRF2), which was the enzymatically hydrolyzed Aoki extract.

[0057] Example 2 FIG. 4 is a step diagram of a method for obtaining a peach and elm wood composite extract according to one embodiment of the present invention.

[0058] Referring to Figure 4, for the complex extraction of Zostera maritima (a kind of yam), 150 kg of Zostera maritima and yam were mixed at a 1:1 ratio. 300 kg of the prepared material was mixed with 3,000 kg of 50% ethanol (1:10, w / w) and extracted for 6 hours at 75±5°C. After extraction, the mixture was cooled to room temperature, filtered through a 0.2μm filter, and concentrated under reduced pressure (55±5°C, 60 bar) to 60 Brix to obtain Zostera maritima complex concentrate (E50) (Lot. No. DJTH-06466). After concentration, the concentrate was mixed with dextrin and purified water and freeze-dried. After freeze-drying, 30 kg of Zostera maritima extract powder (E50) (Lot. No. DJTH-06465) was recovered.

[0059] Experimental example TLC analysis TLC monitoring was performed to determine the presence or absence of oregonin components. The TLC plate was a silica gel plate, the developing solvent was CMW (chloroform:methanol:water=70:30:4), and the experiment was carried out using a UV detector and color-developing reagents such as 10% H2SO4, p-Anisaldehyde H2SO4, and FeCl3.

[0060] FIG. 5 shows the results of TLC analysis of the obtained extract.

[0061] Referring to Figure 5, when comparing the Rf values ​​of oregonin and each sample in the TLC monitoring experiment, spots and hues were observed in all samples at the same positions as oregonin, which qualitatively confirmed that each sample contained oregonin as an active ingredient.

[0062] In particular, the spots of the glycoside compound oregonin of the following chemical formula 1 in the enzymatically degraded AJRF2 were lightly colored, and the presence of various non-glycosylated compounds including the non-glycosylated compounds hirsutanonolol of the following chemical formula 2 and hirstenone of the following chemical formula 3 was clearly confirmed, indicating that the glycosides were clearly converted into non-glycosylated compounds.

[0063] [C1] [ka]

[0064] [C2] [ka]

[0065] [C3] [ka]

[0066] Figure 6 shows the results of TLC monitoring to understand the changes in components upon enzymatic digestion. Here, the experiment was conducted using a UV detector and color reagents such as 10% H2SO4, p-Anisaldehyde H2SO4, and FeCl3. When AJ60E and AJRF1 were compared with AJRF2, the distinctive feature of the AJRF2 sample was that oregonin was deglycosylated and converted to non-glycosylated forms by enzymatic digestion, resulting in a lighter colored oregonin spot and a darker non-glycosylated spot, as confirmed by qualitative confirmation testing.

[0067] HPLC quantitative analysis Quantitative HPLC analysis was performed to confirm the content of active substances in each sample. Samples were dissolved in HPLC-grade MeOH to prepare 1,000 ppm samples. Analysis was performed using a Waters 2695 Separation module and a 2487 Dual λ Absorbance Detector, with 1% acetic acid and ACN as the mobile phase. After 40 minutes of analysis, a calibration curve for the active substance was obtained (see Figure 7), and a chromatogram was obtained at a wavelength of 280 nm.

[0068] 8 to 10 show the results of HPLC analysis of oregonin components in extracts AJ60E, AJRF1, and AJRF2, respectively.

[0069] Referring to Figures 8 to 10, it was confirmed that the active ingredient oregonin was contained in each of the extract samples (AJ 60E: 238.22 ppm), (AJRF1: 583.59 ppm), and AJRF2 (ND) at 1,000 ppm.

[0070] Through this, the oregonin content of the solvent-fractionated AJRF1 was analyzed, and it was confirmed that the oregonin content increased by about 244% compared to AJ60E.

[0071] In the case of enzymatically degraded AJRF2, oregonin content decreased as sugars were lost through enzymatic degradation, and it was confirmed that the oregonin content decreased by more than 94% compared to AJ60E.

[0072] 11 to 13 show the results of HPLC analysis of the hirsutanonol and hirsutenonone components in extracts AJ60E, AJRF1, and AJRF2, respectively.

[0073] 11 to 13, the non-glycosylated components of AJ60E and AJRF1 were difficult to detect because they were very low before enzymatic degradation. However, in AJRF2, as oregonin was deglycosylated by enzymatic degradation, the oregonin content decreased by more than 94% compared to AJ60E. The peaks for the resulting non-glycosylated components, hirsutanonol and hirsutenonone, were observed at 16.261 min and 23.013 min, respectively, with hirsutanonol at 247.70 ppm and hirsutenonone at 314.33 ppm. As a result, hirsutanonol and hirsutenonone increased by 247.70% and 314.33%, respectively.

[0074] Improves periodontal disease In this experimental example, in order to confirm the therapeutic and ameliorative effects of periodontal disease, an inflammatory environment composition model for periodontal disease was first constructed by the following method.

[0075] 1) Analysis of intracellular inflammatory cytokine expression levels -Endogenous inflammatory environment composition model (1) Gingival fibroblasts were dispensed into a 12-well plate at a density of 1x105 / well and cultured for 12 hours. (2) Treatment with 10 ng / ml of TNFα and a test substance at a specified concentration followed by further incubation. (3) Extract RNA from cultured cells using a total RNA extraction kit. (4) Synthesize cDNA using a reverse transcription kit. (5) Quantitative RT-PCR was performed using SYBR reagent, and specific primers for three types of pro-inflammatory cytokines (TNFα, IL-6, IL-1β, etc.) were used to derive the Ct (cycle threshold) value. (6) The relative expression levels of pro-inflammatory cytokines were analyzed using the △△Ct method.

[0076] -Exogenous inflammatory environment composition model (1) Gingival fibroblasts were dispensed into a 12-well plate at a density of 1x105 / well and cultured for 12 hours. (2) After treatment with LPS (1 μg / ml) derived from oral bacteria (such as Porphyromonas gingivalis) or extracellular vesicles and a specified concentration of the test substance, the cells were further cultured. (3) Extract RNA from cultured cells using a total RNA extraction kit. (4) Synthesize cDNA using a reverse transcription kit. (5) Quantitative RT-PCR was performed using SYBR reagent, and specific primers for three types of pro-inflammatory cytokines (TNFα, IL-6, IL-1β, etc.) were used to derive the Ct (cycle threshold) value. (6) The relative expression levels of pro-inflammatory cytokines were analyzed using the △△Ct method.

[0077] 2) Evaluation of intracellular inflammatory signaling molecular mechanisms -Endogenous inflammatory environment composition model (1) Gingival fibroblasts were dispensed into a 12-well plate at a density of 1x105 / well and cultured for 12 hours. (2) Treatment with 10 ng / ml of TNFα and a test substance at a specified concentration followed by further incubation. (3) After cell lysis with Laemmli sample buffer, total protein was extracted from cultured cells by sonication and heating at 95°C for 5 minutes. (4) After SDS-PAGE, proteins were transferred to a PVDF membrane and blocked by immersing the membrane in 5% skim milk for 30 minutes. (5) Quantification of chemiluminescence signals after binding with specific antibodies for phospho NFκB, phospho STAT3, total NFκB, and total STAT3.

[0078] -Exogenous inflammatory environment composition model (1) Gingival fibroblasts were dispensed into a 12-well plate at a density of 1x105 / well and cultured for 12 hours. (2) After treatment with LPS (1 μg / ml) derived from oral bacteria (such as Porphyromonas gingivalis) or extracellular vesicles and a specified concentration of the test substance, the cells were further cultured. (3) After cell lysis with Laemmli sample buffer, total protein was extracted from cultured cells by sonication and heating at 95°C for 5 minutes. (4) After SDS-PAGE, proteins were transferred to a PVDF membrane and blocked by immersing the membrane in 5% skim milk for 30 minutes. (5) Quantification of chemiluminescence signals after binding with specific antibodies for phospho NFκB, phospho STAT3, total NFκB, and total STAT3.

[0079] The inflammation-ameliorating effect of fibroblasts in the model constructed by the above method was analyzed as follows.

[0080] FIG. 14 shows the results of an analysis of the expression level of TNFα. 14, it can be seen that all samples containing oregonin, a glycoside compound derived from Orinum spp., and the non-glycosylated compounds hirsutanonol and hirsutenone, statistically significantly and strongly suppressed the expression of TNFα. This is believed to be a result that contributes to the aggravation of symptoms in inflammation-related diseases and blocking the immunological chain reaction. In addition, it can be seen that the combined extract of Orinum spp. and Orinum spp. (UM / A 50E) also strongly and statistically significantly suppressed the expression of TNFα due to the inclusion of oregonin, a glycoside compound derived from Orinum spp.

[0081] FIG. 15 shows the results of an analysis of the amount of IL-6 expression.

[0082] Referring to Figure 15, it can be seen that all samples containing oregonin, a glycoside compound derived from alder, and the non-glycosylated compounds hirsutanonol and hirsutenone, statistically significantly and strongly suppressed IL-6 expression.

[0083] Additionally, the AJ60E extract had an oregonin content of 238.22 μg / ml, while AJRF1 had an oregonin content of 583.59 μg / ml, making it a high-oregonin extract with 244.98% more oregonin than AJ60E. The results of this experiment confirmed that the higher the oregonin content, the more potently it inhibits IL-6 expression.

[0084] Furthermore, the enzymatic hydrolysate, which produced a high content of non-glycosylated compounds with a significantly increased content of non-glycosylated compounds, is an indicator substance of alder, and is a glycoside compound well known as an effective substance. AJRF2 contains hirsutanonol and hirsutenone, which are representative non-glycosylated compounds that can be derived from oregonin through enzymatic hydrolysis. It has been confirmed that AJRF2 has the most potent inhibitory effect on IL-6 expression among all the extracts produced from alder.

[0085] It was also confirmed that the composite extract of elm and alder (UM / A 50E) contains oregonin, a glycoside compound of alder, and thus has a statistically significant and potent suppression of IL-6 expression.

[0086] FIG. 16 shows the results of analyzing the expression level of IL-1β.

[0087] Referring to Figure 16, it can be seen that all samples containing oregonin, a glycoside compound derived from alder, and the non-glycosylated compounds hirsutanonol and hirsutenone, showed statistically significant and very strong inhibition of IL-1β expression.

[0088] In particular, by regulating the expression of IL-1β, a representative compound of inflammatory cytokines, it is believed that it will be applicable in future immune-related disease and inflammatory disease models. Furthermore, the elm and alder composite extract (UM / A 50E) contains oregonin, a compound of alder glycosides, and has been confirmed to strongly suppress the expression of IL-1β with statistical significance.

[0089] As described above, the pharmaceutical or food composition for preventing and treating periodontal disease containing the extract of an Alder plant according to the present invention as an active ingredient contains oregonin or its non-glycosylated form and has excellent effects on improving, preventing, and treating periodontal disease.

[0090] Therefore, the composition containing the alder extract of the present invention as an active ingredient can be used as a pharmaceutical composition or food composition, as well as an ingredient in toothpaste and mouthwash for humans and animals, and can also be used as animal feed for pets. [Industrial Applicability]

[0091] The composition according to the present invention has industrial applicability as a therapeutic agent, etc.

Claims

1. A pharmaceutical composition for preventing and treating periodontal disease, comprising an extract of an Alnus plant as an active ingredient.

2. 2. The pharmaceutical composition for preventing and treating periodontal disease according to claim 1, wherein the extract of the alder plant contains any one of the following compounds: [Chemical formula 1] 【Chemistry 1】 [Chemical 2] 【Chemistry 2】 [Chemical 3] 【Transformation 3】

3. 3. The pharmaceutical composition for preventing and treating periodontal disease according to claim 2, wherein the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

4. The pharmaceutical composition for preventing and treating periodontal disease according to any one of claims 1 to 3, further comprising an extract of Ulmus.

5. A food composition for preventing and improving periodontal disease, comprising an extract of an Alnus plant as an active ingredient.

6. The food composition for preventing and improving periodontal disease according to claim 5, wherein the alder plant extract contains any one of the following compounds: [Chemical formula 1] 【Chemistry 4】 [Chemical 2] 【Transformation 5】 [Chemical 3] 【Transformation 6】

7. 7. The food composition for preventing and improving periodontal disease according to claim 6, wherein the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

8. The pharmaceutical composition for preventing and treating periodontal disease according to any one of claims 5 to 7, further comprising an extract of Ulmus.

9. A toothpaste or mouthwash composition comprising an extract of an Alnus plant as an active ingredient.

10. The toothpaste or mouthwash composition according to claim 9, wherein the alder extract contains any one of the following compounds: [Chemical formula 1] 【Transformation 7】 [Chemical 2] 【Transformation 8】 [Chemical 3] 【Chemistry 9】

11. The toothpaste or mouthwash composition according to claim 10, wherein the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

12. 12. The toothpaste or mouthwash composition according to any one of claims 9 to 11, further comprising an extract of Ulmus.

13. Feed containing alder (Alnus) plant extract as an active ingredient.

14. 14. The feed of claim 13, wherein the alder extract contains any one of the following compounds: [Chemical formula 1] 【Chemistry 10】 [Chemical 2] 【Chemistry 11】 [Chemical 3] 【Chemistry 12】

15. 15. The feed according to claim 14, wherein the compounds of Formulas 2 and 2 are obtained by enzymatically hydrolyzing the extract of the alder plant.

16. The feed according to any one of claims 13 to 15, wherein the pharmaceutical composition for preventing and treating periodontal disease further comprises an extract of Ulmus.

Images